“Data from passive surveillance during post-authorization use in other countries indicate a higher-than-expected rate of myocarditis and pericarditis associated with the vaccine,” the briefing document noted
A vaccine that may entice some people who have been hesitant to get vaccinated against COVID-19 appears to be highly effective, Food and Drug Administration scientists concluded in documents released Friday.
The vaccine, made by Novavax, Inc., of Gaithersburg, Md., was about 90% effective at preventing mild, moderate and severe COVID-19 when tested in a study involving about 30,000 volunteers ages 18 and older, according to the FDA.
The FDA scientists did, however, say a handful of cases of a rare form of heart inflammation that occurred among vaccine recipients is “concerning.” The condition also been seen rarely in people who received other COVID-19 vaccines. In a statement, Novavax said “there is insufficient evidence to establish a causal relationship” between the vaccine and those cases.
Novavax Patent – Name of the Beast
https://patents.justia.com/patent/11253585
The Mark of the Beast System is real and here!
Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.
#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus #Christ
Leave a Reply